Keywords: UCB, Amgen, Romosozumab, Fracture healing, Post-menopausal osteoporosis

UCB and Amgen not to progress development of romosozumab for fracture healing

Article | 13 February 2013

Print This

Belgium’s leading drugmaker UCB (Euronext Brussels: UCB) and its partner, US biotech giant Amgen (Nasdaq: AMGN) have decided ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in